News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

US FDA Should Warn About Eczema Drug Risk-Panel


10/19/2005 5:12:45 PM

Two topical creams used to treat the skin condition eczema need a stronger warning on their labels about the possible risk of cancer, U.S. medical experts said on Tuesday. The panelists told the U.S. Food and Drug Administration that the drugs, which include Novartis AG's Elidel and Fujisawa Healthcare Inc.'s Protopic, should have a so-called black box warning that also would emphasize that the medicines should not be used in patients younger than two. Panel members said they were concerned the companies were aggressively advertising the medicines to treat infants and others with skin problems the creams are not approved to treat.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES